Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $28.14 Average PT from Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has earned an average recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $28.1429.

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target on the stock. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th.

Insider Buying and Selling

In related news, insider Timothy P. Moran sold 8,759 shares of Kestra Medical Technologies stock in a transaction on Friday, July 31st. The shares were sold at an average price of $22.61, for a total value of $198,040.99. Following the transaction, the insider owned 68,725 shares in the company, valued at $1,553,872.25. This trade represents a 11.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci S. Umberger sold 8,752 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $22.60, for a total transaction of $197,795.20. Following the transaction, the insider directly owned 206,995 shares in the company, valued at $4,678,087. This trade represents a 4.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 223,164 shares of company stock worth $5,288,752 over the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the last quarter. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies in the 1st quarter worth $11,036,000. Brown Advisory Inc. grew its stake in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the period. Finally, Summit Partners Public Asset Management LLC bought a new stake in Kestra Medical Technologies in the fourth quarter valued at about $9,282,000.

Kestra Medical Technologies Stock Down 0.7%

KMTS stock opened at $27.82 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies has a 12 month low of $15.42 and a 12 month high of $30.00. The firm has a market capitalization of $1.63 billion, a PE ratio of -11.50 and a beta of 0.58. The company’s 50 day simple moving average is $23.97 and its 200-day simple moving average is $22.72.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million during the quarter. Equities analysts expect that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.